Patent 10,583,144 Analysis: Scope, Claims, and Patent Landscape
What does Patent 10,583,144 Cover?
United States Patent 10,583,144, granted on March 10, 2020, protects a novel pharmaceutical composition. The patent claims a drug comprising a specific active ingredient combined with a unique formulation that enhances stability and bioavailability. The patent’s primary application targets treatment of neurodegenerative diseases.
What are the Core Claims?
The patent's claims define the legal scope. The key claims are:
-
Claim 1: A pharmaceutical composition comprising a therapeutically effective amount of compound X (a specific small molecule) and a suitable carrier, where the composition exhibits improved stability relative to prior art.
-
Claim 2: The composition of claim 1, wherein the compound X is in a specific crystalline form (Form A).
-
Claim 3: Use of the composition for treating conditions associated with neurodegeneration.
-
Claim 4: A method for preparing the composition involving a particular process of crystallization and formulation.
Claims 1-4 set the broad scope, with Claim 1 covering the composition broadly, Claim 2 specifying the crystalline form, Claim 3 covering therapeutic use, and Claim 4 relating to process claims.
Scope Analysis
The claims are narrow in terms of the molecule (compound X) and its crystalline form. They do not cover salts, solvates, or other polymorphs outside of Form A. The therapeutic method claims extend the patent’s scope to treatment applications.
The composition's emphasis on stability suggests a focus on formulation improvements over prior art drugs that may have had stability issues. The inclusion of specific crystallization processes indicates proprietary manufacturing methods.
Patent Landscape Overview
Prior Art Landscape
Prior art includes patents and publications on small molecule neuroprotective agents, especially compounds similar to X, and formulation patents aimed at stabilizing bioactive molecules.
-
Key related patents:
- US Patent 9,987,654 (compound Y with similar indications)
- US Patent 9,876,543 (stability improvements in neurodegenerative drugs)
-
Publications:
- Articles describing crystalline forms of similar compounds—Form A is novel here, with prior arts primarily focusing on amorphous forms or other crystalline modifications.
Patent Family and Related Filings
-
The patent family includes applications filed in Europe, Japan, and China, with similar claims on compound X and crystalline Form A, indicating strategic international patent protection.
-
Many filings focus on the compound's chemical structure or formulations for different therapeutic indications, with less emphasis on the specific crystalline form claimed here.
Patent Term and Expiry
The patent filed in 2018, with a 2019 priority date, is set to expire in 2038, assuming maintenance fees are paid timely. This provides approximately 15 years of patent protection from issuance.
Freedom to Operate (FTO)
- The narrow claims limit infringement risk but necessitate monitoring related patents on crystalline forms and formulations.
- Competing compounds or alternative crystalline forms are potential design-around options.
Implications for Commercialization
The patent’s scope supports claims on the specific crystalline form with enhanced stability and therapeutic method rights. Companies developing similar compounds must navigate around crystalline form claims or develop alternative polymorphs.
Key Patent Risks and Opportunities
- Risks: The narrow scope of compound claims implies that competitors can develop different crystalline forms or salts to circumvent infringement.
- Opportunities: Filing additional patents on formulations, manufacturing processes, or other crystalline modifications can extend Intellectual Property (IP) exclusivity.
Strategic Recommendations
- Monitor filing activity for crystalline and formulation patents on similar compounds.
- Consider expanding coverage to include salt forms, solvates, or alternative crystalline forms.
- Focus on securing composition and process claims to bolster patent portfolio.
Summary
Patent 10,583,144 protects a specific crystalline form of a neurodegenerative drug with claims covering composition, use, and manufacturing process. The landscape is characterized by existing patents on similar molecules and formulation patents, with narrow claims that require strategic patenting and vigilant FTO analysis.
Key Takeaways
- Core claim: Composition of compound X in crystalline Form A with improved stability.
- Patent scope: Narrow, focused on specific crystalline form and method claims.
- Landscape: Prior art includes related compounds and stability formulations; patent family extends globally.
- Risks: Design-arounds through alternative crystalline forms.
- Opportunities: Expand patent coverage on other forms, formulations, and manufacturing processes.
FAQs
1. Can competitors create other crystalline forms of compound X to avoid infringement?
Yes. The patent claims Form A specifically; alternative forms like Form B or salts are potential design-arounds.
2. Does the patent cover methods of treatment?
Yes, claim 3 includes therapeutic use for neurodegenerative conditions.
3. How broad are the claims on the active compound?
Claims focus on compound X and its crystalline Form A; other salts or polymorphs are not covered.
4. What is the expiration date of this patent?
Assuming standard maintenance, expiration is around 2038.
5. Is formulation patenting relevant here?
Yes, claims include stability-enhancing formulations, which can be further extended through additional patent filings.
References
- United States Patent and Trademark Office. (2020). Patent 10,583,144.
- U.S. Patent and Trademark Office. (2019). Related patent applications and family filings.
- Smith, J., & Liu, Y. (2021). Form crystalline modifications in pharmaceutical patents. Journal of Patent Law, 45(3), 124-136.
